Non-coding RNAs as therapeutic targets in hepatocellular cancer

Chiara Braconi, Tushar C Patel

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy that affects a large number of patients worldwide, with an increasing incidence in the United States and Europe. The therapies that are currently available for patients with inoperable HCC have limited benefits. Although molecular targeted therapies against selected cell signaling pathways have shown some promising results, their impact has been minimal. There is a need to identify and explore other targets for the development of novel therapeutics. Several non-protein coding RNAs (ncRNA) have recently been implicated in hepatocarcinogenesis and tumor progression. These ncRNA genes represent promising targets for cancer. However, therapeutic targeting of ncRNA genes has not been employed for HCC. The use of antisense oligonucleotides and viral vector delivery approaches have been shown to be feasible approaches to modulate ncRNA expression. HCC is an optimal cancer to evaluate novel RNA based therapeutic approaches because of the potential of effective delivery and uptake of therapeutic agents to the liver. In this review, we discuss selected ncRNA that could function as potential targets in HCC treatment and outline approaches to target ncRNA expression. Future challenges include the need to achieve site-specific targeting with acceptable safety and efficacy.

Original languageEnglish (US)
Pages (from-to)1073-1080
Number of pages8
JournalCurrent Cancer Drug Targets
Volume12
Issue number9
StatePublished - 2012

Fingerprint

Untranslated RNA
Liver Neoplasms
Hepatocellular Carcinoma
Neoplasms
Therapeutics
Molecular Targeted Therapy
Antisense Oligonucleotides
Genes
RNA
Safety
Liver
Incidence

Keywords

  • Antagomirs
  • HCC
  • LNA-antimiR
  • miRNA
  • Non-coding RNA
  • Ultraconserved

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Non-coding RNAs as therapeutic targets in hepatocellular cancer. / Braconi, Chiara; Patel, Tushar C.

In: Current Cancer Drug Targets, Vol. 12, No. 9, 2012, p. 1073-1080.

Research output: Contribution to journalArticle

@article{06818840e2e044b1af71fd988f062c03,
title = "Non-coding RNAs as therapeutic targets in hepatocellular cancer",
abstract = "Hepatocellular carcinoma (HCC) is a common malignancy that affects a large number of patients worldwide, with an increasing incidence in the United States and Europe. The therapies that are currently available for patients with inoperable HCC have limited benefits. Although molecular targeted therapies against selected cell signaling pathways have shown some promising results, their impact has been minimal. There is a need to identify and explore other targets for the development of novel therapeutics. Several non-protein coding RNAs (ncRNA) have recently been implicated in hepatocarcinogenesis and tumor progression. These ncRNA genes represent promising targets for cancer. However, therapeutic targeting of ncRNA genes has not been employed for HCC. The use of antisense oligonucleotides and viral vector delivery approaches have been shown to be feasible approaches to modulate ncRNA expression. HCC is an optimal cancer to evaluate novel RNA based therapeutic approaches because of the potential of effective delivery and uptake of therapeutic agents to the liver. In this review, we discuss selected ncRNA that could function as potential targets in HCC treatment and outline approaches to target ncRNA expression. Future challenges include the need to achieve site-specific targeting with acceptable safety and efficacy.",
keywords = "Antagomirs, HCC, LNA-antimiR, miRNA, Non-coding RNA, Ultraconserved",
author = "Chiara Braconi and Patel, {Tushar C}",
year = "2012",
language = "English (US)",
volume = "12",
pages = "1073--1080",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Non-coding RNAs as therapeutic targets in hepatocellular cancer

AU - Braconi, Chiara

AU - Patel, Tushar C

PY - 2012

Y1 - 2012

N2 - Hepatocellular carcinoma (HCC) is a common malignancy that affects a large number of patients worldwide, with an increasing incidence in the United States and Europe. The therapies that are currently available for patients with inoperable HCC have limited benefits. Although molecular targeted therapies against selected cell signaling pathways have shown some promising results, their impact has been minimal. There is a need to identify and explore other targets for the development of novel therapeutics. Several non-protein coding RNAs (ncRNA) have recently been implicated in hepatocarcinogenesis and tumor progression. These ncRNA genes represent promising targets for cancer. However, therapeutic targeting of ncRNA genes has not been employed for HCC. The use of antisense oligonucleotides and viral vector delivery approaches have been shown to be feasible approaches to modulate ncRNA expression. HCC is an optimal cancer to evaluate novel RNA based therapeutic approaches because of the potential of effective delivery and uptake of therapeutic agents to the liver. In this review, we discuss selected ncRNA that could function as potential targets in HCC treatment and outline approaches to target ncRNA expression. Future challenges include the need to achieve site-specific targeting with acceptable safety and efficacy.

AB - Hepatocellular carcinoma (HCC) is a common malignancy that affects a large number of patients worldwide, with an increasing incidence in the United States and Europe. The therapies that are currently available for patients with inoperable HCC have limited benefits. Although molecular targeted therapies against selected cell signaling pathways have shown some promising results, their impact has been minimal. There is a need to identify and explore other targets for the development of novel therapeutics. Several non-protein coding RNAs (ncRNA) have recently been implicated in hepatocarcinogenesis and tumor progression. These ncRNA genes represent promising targets for cancer. However, therapeutic targeting of ncRNA genes has not been employed for HCC. The use of antisense oligonucleotides and viral vector delivery approaches have been shown to be feasible approaches to modulate ncRNA expression. HCC is an optimal cancer to evaluate novel RNA based therapeutic approaches because of the potential of effective delivery and uptake of therapeutic agents to the liver. In this review, we discuss selected ncRNA that could function as potential targets in HCC treatment and outline approaches to target ncRNA expression. Future challenges include the need to achieve site-specific targeting with acceptable safety and efficacy.

KW - Antagomirs

KW - HCC

KW - LNA-antimiR

KW - miRNA

KW - Non-coding RNA

KW - Ultraconserved

UR - http://www.scopus.com/inward/record.url?scp=84872569720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872569720&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1073

EP - 1080

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 9

ER -